{
    "nct_id": "NCT05223920",
    "official_title": "A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients With Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study",
    "inclusion_criteria": "* Completed at least one Treatment Period (TP) in a prior bomedemstat Myeloproliferative Neoplasm (MPN) protocol (such as, but not limited to, IMG-7289-CTP-102/MK-3543-002 or IMG-7289-CTP-201/MK-3543-003).\n* In the estimation of the Investigator, the risk-benefit favors continued dosing with bomedemstat.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Ongoing participation in another investigational study (except observational studies).\n* A history of non-compliance in a prior bomedemstat study (excluding dose suspensions that were medically warranted).\n* Current use of a prohibited medication (e.g., romiplostim).\n* Medical, psychiatric, cognitive, or other conditions that, in the Investigator's opinion, compromise the patient's safety, ability to give informed consent, or comply with the trial protocol.\n* Females who are pregnant or breastfeeding or plan to become pregnant or breastfeed during the study.\n* Women of childbearing potential (WOCBP) and fertile men unwilling to agree to use an approved method of contraception from time of enrollment until 14 days after last bomedemstat dose.",
    "miscellaneous_criteria": ""
}